INTRODUCTION AND OBJECTIVES: Although radical prostatectomy (RP) offers a high overall cancer control rate, even in appropriately selected men, up to a third will experience failure (biochemical recurrence: BCR). PSA has been particularly considered valuable for the detection of BCR defined as a PSA concentration of at least 0.2 ng/ml. Recently, the will to detect the earliest sign of recurrence have led to the development of ultrasensitive PSAs (uPSA), but the usefulness of ultrasensitive assays has not been established. As [-2]proPSA (p2PSA), introduced in clinical practice with its derivate PHI (prostate health index), is normally expressed in pg/mL, it could be more sensible than PSA and uPSA for detecting early BCR after RP. In this study we test the hypothesis that p2PSA (index test) may detect BCR earlier than reference standard test (tPSA) in patients who underwent RP for localised prostate cancer (PCa).
METHODS: The current study is an observational, prospective, cohort study in a contemporary series of consecutive patients subjected to RP for clinically localized PCa from January 2013 to June 2013. Biochemical follow-up consisted of a blood sample for reference standard test (PSA) and index test (p2PSA), after 3-6-12-18-24-30-36 months. The blood samples were processed with the UniCel DxI800 Immunoassay System analyzer (Beckman Coulter Inc., Brea, CA, USA) and managed according to the criteria described by Semjonow et al using the Hybritech calibration. BCR was defined as a confirmatory PSA concentration of 0.2 ng/ml or greater. A value of 0.8 pg/ml was considered the Limit of Detection (LoD) for p2PSA after RP as previously described. The primary outcome was to investigate the sensitivity of both tests for BCR, while the secondary end point was to determine whether or not results are consisting with different pathological outcome. Descriptive statistical analysis were complemented by Cox proportional hazards models, McNemar test and Kaplan-Meier curves for BCR-free survival by PSA and p2PSA cut-offs RESULTS: Over 145 eligible patients, 134 men were enrolled and were followed-up for 3 years. The frequencies of positive subjects, identified with p2PSA cut-off, were significantly higher in all the followups than frequencies of positive subjects identified with PSA cut-off (p<0.0001). Overall we observed 18 BCR according to PSA. Five patients showed a contemporary increase of PSA and p2PSA, while 9 men presented a p2PSA increase earlier than PSA (mean time 4.9AE3.1 months vs. 18.8AE7.3 respectively). In 4 patients the increase of PSA was not associated with a p2PSA > 0.8 pg/ml. The analysis of KaplanMeier curves for BCR-free survival showed a significant lower time for p2PSA (16.7 mo; 95%CI: 14.1-19.2) respect to PSA (35.6 mo; 95%CI: 34.0-33.2). When subjects were stratified according to stage/grade and margins (positive vs. negative), patients with pT2c-GS3+4/4+3-R1 and pT3a-R0/1 could be considered the target categories, which would benefit more from the p2PSA LoD.
CONCLUSIONS: The current findings confirm that p2PSA could be more sensitive than tPSA in detecting early BCR at a mid termfollow-up (3 years). This is a confirmation of a previous paper of ours with a shorter follow-up (18 months). Further studies with a longer follow-up and larger population remain mandatory before considering p2PSA for clinical practice purposes
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MP28-05 A COMBINATION OF NEW PROTEIN BIOMARKERS REDUCES UNNEEDED PROSTATE BIOPSIES AND IMPROVES THE DETECTION OF PROSTATE CANCER: FINDINGS OF A RECENT STUDY
Pierre Tennstedt*, Thomas Steuber, Hamburg, Germany; Annalisa Macagno, Bruno Golding, Ralph Schiess, Schlieren, Switzerland; Silke Gillessen, St. Gallen, Switzerland INTRODUCTION AND OBJECTIVES: Increased prostate volume due to benign disease leads to many false-positive PSA results and consequently to negative prostate biopsies. Previous research indicated that cancer-related protein biomarkers discovered by a genetic-guided approach using a Pten knock-out mouse model could improve prostate cancer diagnosis. The objective of this study was to evaluate if the protein biomarkers are capable of distinguishing benign disease from prostate cancer in men with enlarged prostates.
METHODS: We conducted a retrospective study of men with a total PSA of 2.0-10 ng/ml, negative DRE and enlarged prostate volume (¼35 ml). Serum samples were collected from men before undergoing prostate biopsy at the Martini-Klinik Hamburg, Germany. All samples were taken between 2011 and 2016 following written patient consent. Serum concentration of CTSD, ICAM1, THBS1, OLFM4, TIMP1, and HYOU1 was measured using immunoassays. In addition, total and free PSA were analyzed to calculate %fPSA using the ADVIA Centaur immunoassay system. RESULTS: Of the 474 men included in this study, 236 men had a negative biopsy and 238 were diagnosed with prostate cancer. % fPSA discriminated among biopsy-positive and negative patients with an AUC ¼ 0.650 (P <0.001; 95% CI ¼ 0.600-0.699). Logistic regression analysis revealed that the combination of the two proteins CTSD and THBS1 yielded an AUC ¼ 0.834 (P <0.001; 95% CI ¼ 0.797-0.871); and when combined with %fPSA, it resulted in an even higher AUC ¼ 0.845 (P <0.001; 95% CI ¼ 0.810-0.880). At 90% sensitivity for prostate cancer, the specificity of the combination including CTSD, THBS1 and %fPSA was 60% indicating that 141 of 236 negative biopsies could have been avoided (see Figure 1) . Independent training on samples collected before March 2013 and testing on the samples thereafter also resulted in a high AUC ¼0.872 (P <0.001; 95% CI ¼ 0.826-0.918) showing reproducibility of the method.
CONCLUSIONS: In patients with elevated PSA, negative DRE and enlarged prostate, the method presented is significantly more accurate than %fPSA alone in determining the absence of prostate cancer. The implementation of the method in clinical practice has the potential to significantly lower the rate of prostate biopsies which are negative for cancer by more than 50%.
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